Beijing Hanmi Pharm. Co., Ltd. (hereinafter referred to as Beijing Hanmi) is the first modern pharmaceutical enterprise invested by Korea in China. It was founded in March 1996 and established in beautiful Airport Development Zone, Shunyi, Beijing, covering an area of 13,600 m2. Beijing Hanmi is a pharmaceutical enterprise jointly invested and constructed by Korea Hanmi Group and Beijing Zizhu Pharm. Co., Ltd. (hereinafter referred to as Zizhu Pharm.).
Besides the headquarters, Beijing Hanmi also established a research center, a GMP factory and sales teams spreading all over the country. A business center having international advanced level was also established in 2008, integrating “research and development, production and sales”. The GMP factory was well designed and built by Korea Art Architecture Design Institute and Jilin Medicine Design Institute jointly in strict accordance with GMP standard, has passed GMP certification by State Food and Drug Administration for the first time in December 2001 and put into operation formally, and has passed new GMP certification at the end of 2015. The research center has an area nearly 4,000 m2, comprises a biology laboratory, a chemical synthesis laboratory and a pharmacology and toxicology laboratory, is equipped with various first-class international drug research facilities and closely cooperates with Korea research and development center, Hanmi drug headquarters, Hanmi fine chemical plant and formula research and development center to constitute an advanced high-end global research and development network. Sales teams spread all cover all provinces, autonomous regions, municipalities directly under the central government and hundreds of cities and counties around China.
The product business of the company involves pediatrics products, gastroenterology products, orthopedics products and anti-infectious drugs. Main products include a dozen of varieties such as Medilac-Vita, Ambrocol, Medilac-S, Lidong, aceclofenac, Ricfen, etc., wherein Medilac-Vita and Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution have become basic permanent drugs for Chinese children and are deeply welcome by extensive doctors and parents.
Beijing Hanmi has acquired China’s “Medical Market Credit Demonstration Unit”, “Trustworthy Brand of Medication for children in Medical Market”, Beijing’s “High-Tech Enterprise”, “Bioengineering and Pharmaceutical Industry Spanning Development Project G20”, Shunyi District’s “Top 100 Regional Economy”, “Advanced Enterprise for Regional Protection Growth”, “Big Taxpayer”, “Advanced Unit of Financial Management”, “Advanced Unit of Labor and Employment” and “Excellent Labor Union”.
The objective of Beijing Hanmi Pharm. Co., Ltd. is to research and develop more than 50 kinds of new products of the heavy weight category up to 2020, expand its drug varieties to the fields of respiratory system, digestive system, cancer therapy and high blood pressure and realize RMB 5 billion annual sales amount.
The year 2021 is the 25th anniversary of Beijing Hanmi Pharm.Co., Ltd. In July of this year, the company invested 300 million yuan to build an intelligent automation warehouse with an area of about 1,800 square meters and the drug workshop called "with the largest oral liquid production line in China". The completion and operation marks the development of Beijing Hanmi industrialization to a new level.
